As biotech stages a big comeback, one NYSE-traded company looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology. This global leader in broad-spectrum antiviral nanomedicines had remarkable news recently, revealing that the antiviral activity of its NV-387 oral treatment against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals. The company believes the NV-387 oral treatment is capable of curing RSV infection. Why is this important? Because there is currently no approved treatment for RSV other than ribavirin. A safe and effective treatment remains an unmet medical need!
RSV is an important disease in infants and children less than 5 years old, as well as in older persons over 65 years old. According to the CDC, each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations of children younger than 5 years old and 100-300 deaths in children younger than 5 years old. It also leads to 60,000-160,000 hospitalizations among adults 65 and older, and 6,000-10,000 deaths of adults 65 and older. Ribavirin is the only currently approved drug for RSV infection, that can be used only as a last resort because of its extensive toxicity that limits its effectiveness. This company’s study has achieved an extremely significant result in the fight against RSV!
to bring you the latest market-moving news.
This message is a paid advertisement sent on behalf of Smallcaps Daily, a third-party advertiser of TickerReport.
This message is a paid advertisement for NanoViricides, Inc. (NYSE American: NNVC) from Smallcaps Daily and Interactive Offers. MarketBeat Media, LLC dba TickerReport receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $7,500. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Smallcaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Interactive Offers' website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC) .
Contact Us | Unsubscribe
© 2006-2024 MarketBeat Media, LLC dba TickerReport.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
0 Response to "Little-known biotech company just had groundbreaking results from a study"
Post a Comment